Non-alcoholic Steatohepatitis Treatment Market Size

Non-alcoholic Steatohepatitis Treatment Market size was valued at USD 6.16 billion in 2024 and is expected to cross USD 50.5 billion by the end of 2037, expanding at more than 18.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of non-alcoholic steatohepatitis treatment is estimated at USD 7.07 billion. The growth of the market is attributed to the growing number of obese people. Obesity is the main cause of fatty liver problems as it increases the accumulation of fatty tissue in the liver. In the United States, about 42% of people are obese, with black adults being about 50% fatter.

Additionally, Indians are more likely to be obese in 2019–21 than in 2015–2016. Compared to one in five people in the past, about one in four is overweight today. In addition, positive results from clinical trials of therapeutic drugs are believed to be among the factors driving the growth of the non-alcoholic steatohepatitis (NASH) drugs market. For example, traces in an analysis of Intercept's phase 3 recovery study of obeticholic acid showed that some positive substances, such as B. OCA 25 mg, achieved important goals of improving liver fibrosis without worsening NASH. In addition, OCA 25 mg demonstrated a double response rate in reducing liver fibrosis without worsening NASH compared to placebo.